SCHEMBL31301302

SCHEMBL31301302

CN(C)c1ccc(NC(=O)c2ncn(-c3ccc(Cl)cc3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.56
SMN1; SMN2 Q16637 6/20 0.55
TP53 P04637 5/20 0.55
POLB P06746 4/20 0.49
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
LMNA P02545 2/20 0.47
ALDH1A1 P00352 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
GAA P10253 1/20 0.47
MAPK1 P28482 1/20 0.47
RECQL P46063 1/20 0.47
MCL1 Q07820 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NR3C1 P04150 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CNR1 P21554 1/20 0.44
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31301393 0.90 TP53 (0.65) MAPTSMN1; SMN2TP53POLBLMNA
SCHEMBL31301494 0.86 MAPT (0.61) MAPTSMN1; SMN2TP53POLBALDH1A1
SCHEMBL31301569 0.84 MAPT (0.78) MAPTSMN1; SMN2TP53POLBNPC1
SCHEMBL31301448 0.84 TP53 (0.77) MAPTSMN1; SMN2TP53POLBLMNA
SCHEMBL31301657 0.83 SMN1; SMN2 (0.58) MAPTSMN1; SMN2TP53POLBNPC1
SCHEMBL31301518 0.83 MAPT (0.58) MAPTSMN1; SMN2TP53POLBNPC1
SCHEMBL31301423 0.81 TP53 (0.58) MAPTSMN1; SMN2TP53POLBLMNA
SCHEMBL31301433 0.81 MAPT (0.70) MAPTSMN1; SMN2TP53POLBNPC1
SCHEMBL31301653 0.81 MAPT (0.66) MAPTSMN1; SMN2TP53POLBNPC1
SCHEMBL31301338 0.80 MAPT (0.63) MAPTSMN1; SMN2TP53POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727549-A2 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS University of Georgia Research Foundation, Inc. (US) 2026-04-22 EP disclosed
US-20260097046-A1 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS UNIV GEORGIA (US) 2026-04-09 US disclosed
WO-2024258900-A2 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097046-A1 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS SUB1, PFN1, HCCS MAPT 4575/4885SMN1; SMN2 4264/4885TP53 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.